Coloplast updates financial targets, shares in focus on Copenhagen exchange

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 13:15.

Coloplast (DK0060448595) remains a closely watched medtech name on Nasdaq Copenhagen as investors weigh its updated financial ambitions and organic growth profile against larger European peers such as Smith & Nephew and Convatec. The Danish group has in recent months communicated refined long-term targets for organic growth, EBIT margin and capital allocation in its Investor Relations material, which frame how the stock is viewed by analysts and institutional holders.

What Coloplast has told investors

Coloplast outlined an ambition of delivering mid- to high-single-digit organic revenue growth over the medium term, supported by its chronic care, ostomy care, continence care and wound and skin care businesses, according to its latest investor presentations and annual report. The company couples this with a target of an EBIT margin in the low-30s in percentage terms, which positions it at the profitable end of the European medtech sector.

Management also emphasizes disciplined capital allocation, combining dividends and share buybacks with selective acquisitions in adjacent product categories, as described in its capital markets communication. Coloplast has historically paid out a substantial share of net profit as dividends, while using bolt-on deals to deepen its footprint in growth segments such as advanced wound care and interventional urology.

Friday focus on sector comparison

On a Friday, many investors compare Coloplast’s performance and valuation with other European healthcare names and broader benchmarks such as the Stoxx Europe 600 Health Care index. Coloplast is typically valued at a premium earnings multiple versus diversified medtech peers due to its above-average margins and stable demand from chronic-care patients.

Analyst reports from major houses such as Goldman Sachs, UBS and Deutsche Bank often highlight Coloplast’s resilient recurring revenue base, which is less sensitive to macroeconomic cycles than many discretionary sectors. At the same time, they flag reimbursement regimes and tender dynamics in key markets such as Germany, the United States and the United Kingdom as structural factors that influence margin development over time.

The product behind the stock

Coloplast generates most of its revenue from medical devices that support people with chronic conditions, including ostomy care products such as SenSura Mio ostomy bags, continence care solutions such as SpeediCath catheters, and wound and skin care lines. These products are prescribed by healthcare professionals and reimbursed by public or private payers in most markets.

Where the stock trades today

The Coloplast shares (DK0060448595) trade on Nasdaq Copenhagen; the latest verified price information is available via the Copenhagen exchange and the company’s Investor Relations pages.

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance. Investors should conduct their own research and, where appropriate, consult a qualified financial advisor before making investment decisions.